PROF
Profound Medical Corp

388
Loading...
Loading...
News
all
press releases
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates (Revised)
Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of -44.75% and +14.35%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
More News
News Placeholder
Profound Medical (PROF) Reports Q2 Loss, Misses Revenue Estimates
Profound Medical (PROF) delivered earnings and revenue surprises of -20.93% and -25.05%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates
Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of -104.20% and +14.35%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Beats Revenue Estimates
Relay Therapeutics (RLAY) delivered earnings and revenue surprises of +16.33% and +35.40%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates
Madrigal (MDGL) delivered earnings and revenue surprises of +45.40% and +32.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Profound Medical (PROF) Reports Q1 Loss, Misses Revenue Estimates
chainwire·4mo ago
News Placeholder
Buy Rating Affirmed for Profound Medical on Reimbursement and Market Expansion Prospects
In a report released today, Rick Wise from Stifel Nicolaus upgraded Profound Medical (PRN Research Report) to a Buy, with a price target of $12.0...
TipRanks Financial Blog·1y ago
News Placeholder
Profound Medical (PROF, $8.27) entered Downtrend as Momentum indicator drops below 0 level on Apr 01, 2024
This indicator may be signaling that PROF's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
Tickeron - Stocks·1y ago
News Placeholder
Profound Medical (PROF, $8.27) price exceeded its 50-day Moving Average on April 01, 2024
This price move could indicate a change in the trend, and may be a sell signal for investors...
Tickeron - Stocks·1y ago
News Placeholder
Profound Medical (NASDAQ:PROF) and Minerva Surgical (NASDAQ:UTRS) Head to Head Survey
Profound Medical (NASDAQ:PROF - Get Free Report) and Minerva Surgical (NASDAQ:UTRS - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the...
Zolmax·1y ago

Latest PROF News

View

Advertisement. Remove ads.

Advertisement. Remove ads.